Highlights Hemostemix Inc.

Equities

HEM

CA4236943060

Delayed Toronto S.E. Other stock markets 09:30:00 2024-05-08 EDT			5-day change	1st Jan Change
0.04 ^CAD	0.00%		+14.29%	-42.86%

04-30	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-06	Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	02-06	CI
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
Hemostemix Inc. Announces That 4Th Heart Study Published in Stem Cell Research & Therapy Confirms Treatment for Heart Disease	23-10-31	CI
Hemostemix Inc. Announces Its Study of NCP-01 Supporting Brain Computer Interfaces Has Been Submitted for Peer Review Publication	23-09-15	CI
Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Hemostemix Inc. Submits its Retrospective Heart Study to Leading Stem Cell Journal	23-08-10	CI
Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-01	CI
Hemostemix Hiring Four Biotechnologists in Montreal, Says Applying for Grants to Fund up to 75% of 5-Year Costs	23-01-23	MT
Hemostemix Announces Letter of Commitment For $250,000 of Funding by McGill University Health Centre Foundation	23-01-19	MT
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
Hemostemix Inc. Announces Evolution of Patented Automated Cell Therapy System	22-11-15	CI
Hemostemix Announces NCP-01 Study to Address Pain	22-10-19	MT
Hemostemix Inc. Announces Exploring Clinical Trial Financing Alternatives	22-10-05	CI
Hemostemix Inc. agreed to Spin-Off PreCerv Inc.	22-08-30	CI
Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections	22-08-30	CI
Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI
Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-30	CI
Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hemostemix Inc.

Equities

HEM

CA4236943060

Highlights

Filters